Urology Experts Publish Guidelines for Best Use of BLC with Cysview® in the Surveillance of Bladder Cancer

• the first follow-up cystoscopy at 3 months after TURBT for intermediate and high-risk patients
• at the 3 and 6 months surveillance cystoscopy, and then every 6 months for high risk patients in the first two years

• prior to intravesical therapy if there is concern for residual disease after TURBT
• use at time of office fulguration and/or biopsy for low grade tumors

“BLC with Cysview has been included in the AUA/SUO guidelines since 2016 and has strong data supporting its use to improve detection of cancer over white light cystoscopy. The 2019 Nature publication provides a road map for when to use BLC with Cysview during office cystoscopy as well as how to integrate it into clinical practice.  The University of Texas Southwestern (UTSW) was the first hospital in the United States to integrate Cysview into the clinic setting for surveillance cystoscopy as well as for TURBT in the operating room.  By using BLC with Cysview for patients in surveillance patient outcomes should improve and provide benefits to patients and those managing Non-Muscle Invasive Bladder Cancer (NMIBC),” says Dr. Yair Lotan M.D., Professor of Urology Helen J. and Robert S, Strauss Professorship in Urology, UTSW and the lead author on the Consensus paper.